NTRK2 and telomere syndrome: Both TRKB and cmet proteins were significantly overexpressed in malignant STS compared with benign sarcomas (P=0.001 and 0.015, respectively) and TRKB overexpression was higher in cases with metastatic recurrence compared with local or no recurrence (P=0.05) (Supplementary Figure S4).